Bullous Pemphigoid Epidemiology Forecast 2025-2034

Bullous pemphigoid (BP) is a rare autoimmune skin disease that causes large fluid-filled blisters on the skin. Studies indicate that the incidence of bullous pemphigoid is increasing and ranges between 2 to 22/1,000,000 worldwide. In Europe, the estimated prevalence is reported to be 4,000.

Bullous Pemphigoid Epidemiology Forecast Report Coverage

The “Bullous Pemphigoid Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of bullous pemphigoid. It projects the future incidence and prevalence rates of bullous pemphigoid across various populations. The study covers age and type as major determinants of the Bullous Pemphigoid-affected population. The report highlights patterns in the prevalence of bullous pemphigoid over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of bullous pemphigoid in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Bullous Pemphigoid: Disease Overview

Bullous pemphigoid refers to a rare autoimmune skin disease that usually starts with an itchy, raised rash. In this condition, the immune system of the body starts attacking healthy skin tissue, leading to large fluid-filled blisters and sometimes open sores. The average age of onset of this disease is estimated to be 65 years. Bullous pemphigoid is reported to occur throughout the world, with no apparent racial predilection.

Bullous Pemphigoid: Treatment Overview

Steroid tablets, such as prednisone or prednisolone, are considered the primary treatment for bullous pemphigoid. Doxycycline, azathioprine, mycophenolate, dapsone, methotrexate, or intravenous immunoglobulin are some of the other drugs that are often added to the treatment regimen to reduce the dose of steroids and minimize associated side effects. Long-term remission is usually observed in most of the patients after 2 to 3 years of treatment. However, some patients experience require treatment for years.

Epidemiology

The bullous pemphigoid epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for bullous pemphigoid by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for bullous pemphigoid and their trends. The data is broken down into specific categories, such as the total diagnosed cases across different age groups and patient pools.

• The incidence of bullous pemphigoid is increasing, as per the Orphanet. The incidence is reported to range between 2 to 22 cases/1,000,000 worldwide.
• A 2022 meta-analysis in the British Journal of Dermatology reported a cumulative bullous pemphigoid incidence of 8.2 per million people and an incidence rate of 34.2 per million person-years.
• Research shows that bullous pemphigoid predominantly affects older adults with an average age of 80 years. In 10% to 20% of the cases, mucosal involvement is observed.
• According to a study published in the Frontiers of Medicine (2018), the annual incidence of bullous pemphigoid is estimated to be between 2.4 and 23 cases per million among the general population. In people above 80 years, the incidence is reported to be 190 to 312 cases per million.

Country-wise Bullous Pemphigoid Epidemiology

The bullous pemphigoid epidemiology data and findings for the United States, EU-4 (Germany, Spain, Italy, France), the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of bullous pemphigoid varies significantly between countries owing to the differences in genetic predispositions, environmental triggers (including infections and allergens), the size of the aging population, and variations in healthcare access and diagnostic capabilities. In Europe, the estimated prevalence of bullous pemphigoid is reported to be 1/4000.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of bullous pemphigoid based on several factors.
• Bullous Pemphigoid Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population, and the unmet needs of bullous pemphigoid are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of bullous pemphigoid epidemiology in the 8 major markets?
• What will be the total number of patients with bullous pemphigoid across the 8 major markets during the forecast period?
• What was the country-wise prevalence of bullous pemphigoid in the 8 major markets in the historical period?
• Which country will have the highest number of bullous pemphigoid patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of bullous pemphigoid during the forecast period of 2025-2034?
• What are the currently available treatments for bullous pemphigoid?
• What are the disease risks, signs, symptoms, and unmet needs of bullous pemphigoid?

This product will be delivered within 3-5 business days.